• 검색 결과가 없습니다.

Reversal of Early Central Retinal Vein Occlusion by Alleviating Optic Nerve Edema with an Intravitreal Dexamethasone Implant

N/A
N/A
Protected

Academic year: 2022

Share "Reversal of Early Central Retinal Vein Occlusion by Alleviating Optic Nerve Edema with an Intravitreal Dexamethasone Implant"

Copied!
2
0
0

로드 중.... (전체 텍스트 보기)

전체 글

(1)

Case Report pISSN: 1011-8942 eISSN: 2092-9382

Korean J Ophthalmol 2014;28(2):192-193 http://dx.doi.org/10.3341/kjo.2014.28.2.192

© 2014 The Korean Ophthalmological Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

192

Reversal of Early Central Retinal Vein Occlusion by Alleviating Optic Nerve Edema with an Intravitreal Dexamethasone Implant

Young Joo Cho, Dong Hyun Lee, Hae Min Kang, Min Kim, Hyoung Jun Koh

Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea

The SCORE (Standard Care vs Corticosteroid for Reti- nal Vein Occlusion) study revealed the benefit of steroid treatment in central retinal vein occlusion (CRVO) associ- ated with macular edema (ME) [1]. Herein, we report a case of the reversal of early CRVO with optic disc swelling after intravitreal dexamethasone implant (Ozurdex; Aller- gan Inc., Irvine, CA, USA) injection. This case suggests that early intravitreal dexamethasone implantation may be a good treatment option in CRVO with co-existing optic nerve swelling. This treatment could relieve optic nerve edema causing the occlusion of venous flow, thereby im- proving venous outflow.

Case Report

A 44-year-old female without any previous medical his-

tory visited our clinic because of the sudden onset of inter- mittent blurred vision in her left eye. Her best-corrected visual acuity (BCVA) was 20 / 22 and fundus examination revealed multiple retinal, preretinal, and subretinal hemor- rhages throughout the retina with tortuous retinal veins in her left eye (Fig. 1A). The right eye showed a completely normal fundus. Fluorescein angiography revealed delayed retinal venous filling. Arteriovenous transit time was slight- ly prolonged to 19 seconds and there was faint leakage in the late phase, but no signs of any vascular non-perfusion (Fig. 1B). Cardiologic and neurologic work-up and labora- tory tests (homocysteine, protein C and S, fibrinogen, anti- cardiolipin antibodies, and lupus anticoagulants) were nor- mal except for weakly positive anticardiolipin IgM and mild iron deficiency anemia. The patient denied any val- salva episodes. We decided to observe the patient for the following two weeks without making a diagnosis. Two weeks later, her BCVA was slightly decreased to 20 / 25, and an increased number of retinal hemorrhages with se- vere disc swelling were noted (Fig. 1C), but there was still no sign of ME (Fig. 1D). At this time, the patient preferred to undergo medical intervention to improve her subjective symptom. We discussed with her that the drainage site of This case describes the reversal of early central retinal vein occlusion (CRVO) with disc swelling after intravitreal dexamethasone implant (Ozurdex) injection. A 44-year-old female presented with sudden-onset intermittent blurred vision in her left eye. Fundus examination revealed multiple retinal hemorrhages without macular edema (ME). Two weeks later, an increased number of retinal hemorrhages with severe disc swelling were noted with still no sign of ME. An intravitreal dexamethasone implant was injected. Five days later, there were improvements in disc swelling and retinal hemorrhage. One month later, her subjective visual symptoms were completely improved, and fundus examination revealed marked improvement along with almost complete resolution of disc swelling. Intravitreal dexamethasone implant injection may potentially change the natural course of CRVO progression and its various subsequent complications.

Key Words: Central retinal vein occlusion, Intravitreal dexamethasone implant, Optic nerve edema

Received: December 2, 2013 Accepted: February 6, 2014

Corresponding Author: Hyoung Jun Koh, MD. Department of Ophthal- mology, The Institute of Vision Research, Yonsei University College of Medicine, #50 Yonsei-ro, Seodaemun-gu, Seoul 120-749, Korea. Tel: 82- 2-2019-3440, Fax: 82-2-3463-1049, E-mail: [email protected]

(2)

193 YJ Cho, et al. Reversal of Central Retinal Vein Occlusion with Steroid

the retinal vein is located in the lamina cribrosa within the optic nerve and an intravitreal dexamethasone implant may help alleviate the progression of the vein occlusion by reducing optic nerve edema. The patient agreed to the treatment and an intravitreal dexamethasone implant 0.7 mg was injected.

Five days later, her BCVA was 20 / 22 and there were improvements in disc swelling and retinal hemorrhage (Fig.

1E). One month later, her BCVA improved to 20 / 20 and her subjective visual symptom was completely improved.

Fundus examination revealed marked improvement of ret- inal hemorrhages and vascular tortuosity along with al- most complete resolution of disc swelling (Fig. 1F).

Discussion

A compartment syndrome at the site of the lamina cribrosa is thought to be the key mechanism in the pathophysiology of CRVO. The current treatment strategy for CRVO is typi- cally directed to complications such as ME or neovascular- ization rather than the venous occlusion itself. Although many studies have already shown the benefits of anti-vascu- lar endothelial growth factors or steroids for the treatment of CRVO-associated complications [2,3], this case suggests that even in early CRVO, if associated with optic nerve swelling, steroid treatment could decrease disc swelling, thereby re- lieving compartment obstruction and improving vascular hemorrhage. Steroids may reduce the disc swelling, which subsequently decreases the pressure of the scleral ring and

may improve the venous outflow. This may potentially change the natural course of disease progression of CRVO and its various subsequent complications.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcino- lone with observation to treat vision loss associated with mac- ular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14.

2. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizum- ab for macular edema following central retinal vein occlu- sion: six-month primary end point results of a phase III study.

Ophthalmology 2010;117:1124-33.

3. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sh- am-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Ophthalmology 2010;117:1134-46.

B D

C

A E F

Fig. 1. (A) At first visit, fundus photography (FP) showed multi- ple retinal, preretinal, and subretinal hemorrhages with tortuous retinal vasculature and (B) fluorescein angiography revealed faint leakage during the late phase with no sign of non-perfusion.

(C) Two weeks later, FP showed an increased number of retinal hemorrhages with severe disc swelling and (D) optical coherence tomography revealed no sign of macular edema. (E) Five days after the treatment, FP showed improved disc swelling and hem- orrhages. (F) One month after the treatment, FP showed marked improvement of retinal hemorrhages and vascular tortuosity along with almost complete resolution of disc swelling.

수치

Fig. 1. (A) At first visit, fundus photography (FP) showed multi- multi-ple retinal, preretinal, and subretinal hemorrhages with tortuous  retinal vasculature and (B) fluorescein angiography revealed  faint leakage during the late phase with no sign of non

참조

관련 문서

Conclusion : These results show that the oriental medical treatment can be conservative measure to the macular edema resulted from branch retinal vein

vitreal bevacizumab (Avastin). Economic considerations of macular edema therapies. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Combinatorial

Purpose: To determine changes in subfoveal choroidal thickness (SCT) after intravitreal injection of bevacizumab in eyes with macular edema secondary to retinal vein occlusion

Purpose: To evaluate the efficacy of intravitreal preservative-free triamcinolone acetonide (Maqaid ® ) injection for the treatment of macular edema secondary to retinal vein

Changes of best-corrected visual acuity in logarithm of the minimal angle of resolution in eyes with macular edema secondary to branch retinal vein occlusion (BRVO).. Although

Predictive Factors for a Favorable Response to Intravitreal Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.. 강현구 1 , 서유리 2 , 최은영 1 ,

Purpose: To compare the difference of efficacy between intravitreal dexamethasone implant and bevacizumab injection for patients with branch retinal vein occlusion (BRVO) with

Purpose: To evaluate the 3-month natural course of recurrent macular edema secondary to branch retinal vein occlusion (BRVO) treated with intravitreal bevacizumab.. Methods: